Women's Health

BALTIMORE — Addressing substance use disorders during pregnancy with compassion and understanding is imperative for women’s health providers, according to a speaker at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — Black and Hispanic women may be less likely to receive a recommendation to restrict activity during pregnancy compared with white women, according to research presented at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — A new study found that the Dobbs decision and subsequent restrictive abortion laws are impacting residency application decisions for medical students across all specialties.

BALTIMORE — COVID-19 vaccinations are safe and recommended, even for women who are pregnant or lactating, according to a presenter at a late-breaking session at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — Just over one-quarter of U.S. women with hypertension who are at risk for unintended pregnancy received contraceptive counseling between 2015 and 2019, according to a poster presented at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — The pandemic, political discord, misinformation and what the U.S. Surgeon General has called an “epidemic of loneliness and isolation,” confront OB/GYN providers as intensely as the rest of the population, according to a speaker.

BALTIMORE — Treatment with once-daily oral fezolinetant was effective for reducing moderate to severe hot flashes associated with menopause in a diverse population, according to findings reported at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — Today, the president of the American Congress of Obstetricians and Gynecologists spoke to attendees of the 2023 annual meeting regarding the importance of mental health and overcoming women’s health challenges in the past year.

BALTIMORE — Postpartum depression, a leading cause of maternal death through suicide, should be treated as a public health priority, a speaker at the ACOG Annual Clinical & Scientific Meeting told Healio.

Parties to the federal case seeking to overturn FDA approval of the abortion drug mifepristone presented oral arguments to a panel of three judges in the 5th U.S. Circuit Court of Appeals on Wednesday.